scholarly journals Subclinical memory dysfunction in Malaysian systemic lupus erythematosus patients: Association with clinical characteristics and disease activity – A pilot study

2016 ◽  
Vol 38 (3) ◽  
pp. 189-194 ◽  
Author(s):  
Mohd Shahrir M. Said ◽  
Saiful S. Bin Shudim ◽  
Khairiyah Mohamad ◽  
Syahrul S. Shaharir ◽  
Norella K.C. Tong ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pilot Study ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Clinical Characteristics ◽  
Systemic Lupus ◽  
Memory Dysfunction

Performance and psychometric properties of lupus impact tracker in assessing patient-reported outcomes in pediatric lupus: Report from a pilot study

Lupus ◽  
2020 ◽  
Vol 29 (13) ◽  
pp. 1781-1789
Author(s):  
Suhas K Ganguli ◽  
Joyce S Hui-Yuen ◽  
Meenakshi Jolly ◽  
Jane Cerise ◽  
Barbara Anne Eberhard
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pilot Study ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Patient Reported Outcomes ◽  
Laboratory Data ◽  
Damage Index ◽  
Systemic Lupus ◽  
Patient Reported ◽  
The Mean

Objective To evaluate the reliability, validity, feasibility and psychometric performance of the Lupus Impact Tracker (LIT) as a patient reported outcome (PRO) measure tool in pediatric systemic lupus erythematosus (pSLE). Methods This is a prospective, observational, pilot study where patients aged between 12 and 25 years, fulfilling the 1997 ACR classification criteria for SLE, were enrolled. Over 3 consecutive, routine, clinical visits, the patients completed the LIT alongside the Patient-Reported Outcomes Measurement Information System-Short Forms (PROMIS-SFs), Childhood Health Assessment Questionnaire (CHAQ). Rheumatologists completed the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC-ACR) Damage Index. Demographic, clinical and laboratory data were also collected. Results Of 46 patients enrolled, 38 patients completed 2 visits and 31 completed all 3 visits. Seventy-eight percent were female, 33% African American, 28% Asian, 15% Caucasian and 17% Hispanic. The mean (SD) age was 17.2 (2.7) years, with a mean (SD) disease duration of 4.6 (3.1) years. The mean (SD) SLEDAI-2K at enrollment was 3.54 (2.96). In the 38 patients who completed two or more visits, intra-class correlation coefficient and Cronbach alpha were calculated to be 0.70 and 0.91 respectively, signifying good reliability of LIT. The LIT showed positive correlation with CHAQ-Disability Index and majority of the PROMIS-SFs parameters. Construct validity was established against clinical disease activity (SLEDAI-2K). Conclusion The preliminary results indicate that the LIT is a reliable and valid instrument to capture PRO in p-SLE. Prospective validation with a larger, multicenter cohort is the next step.

Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single-center experience

Lupus ◽  
2016 ◽  
Vol 26 (3) ◽  
pp. 248-254 ◽  
Author(s):  
L Quintanilla-González ◽  
Y Atisha-Fregoso ◽  
L Llorente ◽  
H Fragoso-Loyo
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Clinical Characteristics ◽  
Control Group ◽  
Aggressive Treatment ◽  
Systemic Lupus ◽  
Neurologic Sequelae ◽  
One Year

Objective The purpose of this study was to describe the clinical characteristics of acute transverse myelitis, including the time of their presentation, and to evaluate their effect on accrual damage in patients with systemic lupus erythematosus (SLE). Methods Patients with SLE who were hospitalized because of incident, noninfectious myelitis at our institute between January 1997 and December 2013 were identified. As a control group, we selected for each of the patients in the study group one SLE patient hospitalized at the closest date to the case due to other severe non-neuropsychiatric (NP) SLE manifestation, with no history of NP manifestations or noninfectious disease. Clinical characteristics, laboratory results, treatment, disease activity (SLEDAI-2K), and damage (SLICC/ACR-DI) were collected from medical charts at the index hospitalization and one year after hospitalization. Results Demographics and SLE characteristics, including age at SLE diagnosis and time since SLE diagnosis to hospitalization, were comparable in patients with myelitis and controls. At hospitalization, disease activity and cumulative damage were similar in both groups. Patients with myelitis received more aggressive treatment than controls. One year after hospitalization, two of the 15 patients who completed follow-up had symptom improvement without neurologic sequelae, and 13 of them had some improvement of symptoms with neurologic sequelae. Four patients died in the myelitis group, three of them of infectious diseases, and one of alveolar hemorrhage. No patient died because of myelopathy and in the control group no patient died, although three were lost during the follow-up. Disease activity and treatment did not differ between both groups. However, cumulative damage was higher among the patients with myelitis than controls (1.9 ± 0.9 vs 0.75 ± 0.9; p = 0.003). Conclusion Patients with myelitis have clinical characteristics similar to those observed in non-NP SLE and receive more aggressive treatment. Furthermore, myelitis is associated with a significant increase in accrual damage compared with severe non-NP manifestations.

scholarly journals Juvenile and juvenile-onset systemic lupus erythematosus patients: Clinical characteristics, disease activity and damage

2017 ◽  
Vol 65 (2) ◽  
pp. 49-53 ◽  
Author(s):  
Rasha E. Gheith ◽  
Iman I. El-Gazzar ◽  
Hussein S. El Fishawy ◽  
Abeer M. Nour El-Din ◽  
Dina M.R. Bahgat ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Clinical Characteristics ◽  
Systemic Lupus ◽  
Juvenile Onset ◽  
Onset Systemic Lupus Erythematosus

scholarly journals Hematological Malignancies in Systemic Lupus Erythematosus: Clinical Characteristics, Risk Factors and Prognosis – a Case-control Study

2021 ◽  
Author(s):  
Yuqi Zhang ◽  
Wei Li ◽  
Panpan Zhang ◽  
Jinyan Guo ◽  
Jinlei Sun ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Disease Activity ◽  
Incidence Rate ◽  
Lupus Erythematosus ◽  
Clinical Characteristics ◽  
Hematological Malignancies ◽  
Lower Percentage ◽  
Systemic Lupus ◽  
Dsdna Antibody

Abstract Background: Systemic lupus erythematosus (SLE) is a chronic and complex multi-system autoimmune disorder. Higher risks of malignancy were observed in SLE patients, which was associated with higher mortality. We aimed to explore clinical characteristics, risk factors and prognosis between SLE patients with or without hematological malignancies (HM) in Chinese population.Methods: We retrospectively collected patients from our hospital with a diagnosis of SLE from January 2013 to December 2020. Clinical and laboratory data were collected and disease activity was evaluated according to systemic lupus erythematosus disease activity index-2000 (SLEDAI-2K). Logistic regression analysis was performed to predict risk factors. The survival rate was estimated by Kaplan-Meier and Cox proportional hazards regression analysis.Results: The study enrolled 15 SLE patients with HM as the case group and 57 without HM as the control group for analysis. The incidence rate of HM was approximately 0.24% with elevated standard incidence rate of lymphoma and leukemia (27.559 and 12.708, respectively). Patients with HM were at a higher age at the diagnosis of SLE, with a higher frequency of infection, splenomegaly and a lower level of hemoglobin compared with patients without HM. SLEDAI-2K was comparable between the two groups at the diagnosis of SLE (P = 0.184). Lower percentage of patients with HM expressed positive anti-dsDNA antibody (26.7% vs 66.7%，P = 0.005 ) or had ever been treated with hydroxychloroquine (40.0% vs 86.0%, P = 0.001). Higher age (OR 1.098, P = 0.004), infection (OR 5.759, P = 0.041) and lower hemoglobin (OR 0.954, P = 0.021) were risk factors for SLE patients to develop with HM. Female (RR 0.219, P = 0.009) and hydroxychloroquine (RR 0.281, P = 0.024) were protective factors from mortality. Conclusions: SLE patients are more prone to be complicated with HM, especially for those at a higher age, suffering with infection or anemia. The prognosis of male patients with SLE tends to be poorer whether complicated with HM. The association between antinuclear antibody spectrum and SLE complicated with HM needs further investigation.

scholarly journals P179 Systemic lupus erythematosus, a pilot study of a new disease activity score

2020 ◽  
Author(s):  
Daphna Paran ◽  
Monique Ben-Am ◽  
Liran Mendel ◽  
Ari Polachek ◽  
Victoria Furer ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pilot Study ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Disease Activity Score ◽  
Activity Score ◽  
New Disease ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document